Alethea Capital Management, LLC Spectrum Pharmaceuticals Inc Transaction History

Alethea Capital Management, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$0.65 - $1.31 $24,380 - $49,135	-37,508 Reduced 4.76%	750,465 $720,000
Q2 2022 Aug 15, 2022	SELL	$0.7 - $1.4 $272,399 - $544,798	-389,142 Reduced 33.06%	787,973 $615,000
Q4 2021 Feb 14, 2022	SELL	$1.27 - $2.42 $609,219 - $1.16 Million	-479,700 Reduced 28.95%	1,177,115 $1.5 Million
Q3 2021 Oct 27, 2021	BUY	$2.15 - $3.82 $16,125 - $28,650	7,500 Added 0.45%	1,656,815 $3.61 Million
Q2 2021 Aug 16, 2021	BUY	$2.89 - $4.45 $144,112 - $221,903	49,866 Added 3.12%	1,649,315 $6.19 Million
Q1 2021 May 14, 2021	BUY	$2.9 - $4.09 $172,550 - $243,355	59,500 Added 3.86%	1,599,449 $5.21 Million
Q4 2020 Feb 12, 2021	BUY	$3.38 - $5.14 $212,051 - $322,468	62,737 Added 4.25%	1,539,949 $5.25 Million
Q3 2020 Nov 16, 2020	BUY	$2.99 - $4.9 $1.03 Million - $1.68 Million	342,941 Added 30.23%	1,477,212 $6.03 Million
Q2 2020 Aug 11, 2020	BUY	$2.11 - $3.38 $949,673 - $1.52 Million	450,082 Added 65.78%	1,134,271 $3.83 Million
Q1 2020 May 11, 2020	BUY	$1.83 - $3.45 $1.25 Million - $2.36 Million	684,189 New	684,189 $1.59 Million

115K

Ticker SPPI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 188,164,000
Description
Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include Eflapegrastim, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor ...

Get notified when there are updates to the investment portfolio of Alethea Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Alethea Capital Management, LLC with notifications on news.